|
| |
Takeda San DiegoTakeda San Diego (TSD) is Takeda's global center for excellence in structure-based drug discovery. TSD integrates cutting-edge protein crystallography and drug discovery technologies to efficiently generate Investigational New Drug (IND) candidates for the treatment of metabolic diseases and cancer. Multiple drug candidates discovered at TSD are currently in clinical trials including SYR322, a potential treatment for type II diabetes.
| Contact Details: |
| 10410 Science Center Drive |
| San Diego |
| California |
| 92121 |
| United States of America |
| Tel: | (858) 622-8528 |
| Fax: | (858) 550-0526 |
| Email: | HR@takedasd.com |
| WWW: | www.syrrx.com/
|
|
Loading...
|
Recent Publications by Takeda San Diego: |  |
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Inhibitors of dipeptidyl peptidase IV (DPP-4) have emerged as an important... | 4th February, 2009
| Takeda San Diego, 10410 Science Center Drive, San Diego, CA 92121, USA.
| Curr Top Med Chem. 2008;8(17):1545-52.
|
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
The aim of the present research was to characterize the pharmacokinetic,... | 25th October, 2008
| Takeda San Diego Inc, San Diego, CA 92121, USA.
| Eur J Pharmacol. 2008 Jul 28;589(1-3):306-14. Epub 2008 Apr 26.
DOI Direct Link |
Parallel SFC/MS-MUX screening to assess enantiomeric purity.
Enantiomeric excess (ee) was evaluated for two internally synthesized... | 11th October, 2008
| Department of Analytical Chemistry and Technology, Takeda San Diego, Inc.,
| Chirality. 2008 Aug;20(8):885-95.
DOI Direct Link |
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
BACKGROUND: Alogliptin is a highly selective dipeptidyl peptidase-4... | 2nd October, 2008
| Takeda San Diego, Inc., San Diego, California 92121, USA.
| Clin Ther. 2008 Mar;30(3):513-27.
DOI Direct Link |
Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
A novel series of non-covalent, benzimidazole-based inhibitors of DPP-4... | 9th July, 2008
| Takeda San Diego, Drug Discovery, 10410 Science Center Drive, San Diego,
| Bioorg Med Chem Lett. 2008 Apr 1;18(7):2362-7. Epub 2008 Mar 4.
DOI Direct Link |
→View more Takeda San Diego research publications. |
Press Releases on Takeda San Diego:
|
 |
| Takeda Receives New Information on Alogliptin (SYR-322) NDA |
6th March, 2009 |
Takeda Pharmaceutical Company Limited |
OSAKA, Japan, March 6 /PRNewswire/ -- Takeda Pharmaceutical Company Limited today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary,
|
| FDA Continues Review of Takeda?s New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes |
10th October, 2008 |
Takeda Pharmaceutical Company Limited |
OSAKA, Japan, Oct. 10 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 7361 times since April 2007, the link to the organisation's website has been followed 659 times Recent Search Terms used to find this page: farsenyl | map showing 10410 Science Center Dr., San Diego, CA | takeda san diego | takeda san diego | takeda san diego | takeda san diego | takeda san diego | comercial takeda 24 c.a | comercial takeda 24 c.a | takeda sa | . Search for more companies in San Diego Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Takeda San Diego |
